Gracell Biotechnologies Inc. (GRCL): Price and Financial Metrics
GET POWR RATINGS... FREE!
GRCL POWR Grades
- GRCL scores best on the Sentiment dimension, with a Sentiment rank ahead of 99.51% of US stocks.
- The strongest trend for GRCL is in Sentiment, which has been heading up over the past 179 days.
- GRCL's current lowest rank is in the Momentum metric (where it is better than 4.37% of US stocks).
GRCL Stock Summary
- GRACELL BIOTECHNOLOGIES INC's stock had its IPO on January 8, 2021, making it an older stock than merely 5.76% of US equities in our set.
- GRCL's price/sales ratio is 4,323.38; that's higher than the P/S ratio of 99.89% of US stocks.
- GRACELL BIOTECHNOLOGIES INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -588.96%, greater than the shareholder yield of merely 0.72% of stocks in our set.
- Stocks that are quantitatively similar to GRCL, based on their financial statements, market capitalization, and price volatility, are MTEM, RXDX, MRUS, DTIL, and PRQR.
- GRCL's SEC filings can be seen here. And to visit GRACELL BIOTECHNOLOGIES INC's official web site, go to www.gracellbio.com.
GRCL Stock Price Chart Interactive Chart >
GRCL Price/Volume Stats
| Current price | $3.47 | 52-week high | $15.00 |
| Prev. close | $3.33 | 52-week low | $1.68 |
| Day low | $3.07 | Volume | 28,700 |
| Day high | $3.55 | Avg. volume | 177,368 |
| 50-day MA | $2.90 | Dividend yield | N/A |
| 200-day MA | $3.39 | Market Cap | 234.83M |
Gracell Biotechnologies Inc. (GRCL) Company Bio
Gracell Biotechnologies Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing cell therapies to address medical needs in the treatment of cancer. Gracell Biotechnologies aims to disrupt conventional approaches to CAR-T cell therapies with technology platforms-FasTCAR and TruUCAR.
Latest GRCL News From Around the Web
Below are the latest news stories about GRACELL BIOTECHNOLOGIES INC that investors may wish to consider to help them evaluate GRCL as an investment opportunity.
Gracell Biotechnologies to Participate in Three Upcoming Investor ConferencesGracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one meetings at three investor conferences in September 2022 as follows: |
Gracell Biotechnologies to Participate in Four Upcoming Investor ConferencesGracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one meetings at four investor conferences in September 2022 as follows: |
Gracell Biotechnologies Reports Second Quarter 2022 Unaudited Financial Results and Provides Corporate UpdatePresented updated clinical data from an investigator-initiated trial (IIT) evaluating FasTCAR GC012F for the treatment of relapsed/refractory multiple myeloma (r/r MM) at ASCO and EHA 2022, which underscored the deep response with a 100% MRD negativity ratePresented first-in-human data of GC012F in relapsed/refractory B-cell Non-Hodgkin’s lymphomas (r/r B-NHL) at EHA 2022Presented updated results from an IIT evaluating allogeneic TruUCAR GC502 in relapsed/refractory B-cell acute lymphoblastic le |
Do Institutions Own Gracell Biotechnologies Inc. (NASDAQ:GRCL) Shares?Every investor in Gracell Biotechnologies Inc. ( NASDAQ:GRCL ) should be aware of the most powerful shareholder groups... |
Gracell Biotechnologies to Report Second Quarter 2022 Financial on Monday, August 15, 2022Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it plans to release unaudited financial results for the second quarter ended June 30, 2022 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, August 15, 2022. The management team will host a live audio webcast and con |
GRCL Price Returns
| 1-mo | 52.86% |
| 3-mo | -19.49% |
| 6-mo | 50.87% |
| 1-year | -75.41% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -42.55% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...